BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8562184)

  • 1. Anthracycline resistance in breast cancer: clinical applications of current knowledge.
    Ravdin PM
    Eur J Cancer; 1995; 31A Suppl 7():S11-4. PubMed ID: 8562184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
    Ravdin PM
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer.
    Seymour L; Bezwoda WR; Dansey RD
    Breast Cancer Res Treat; 1995; 36(1):61-9. PubMed ID: 7579508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug resistance in breast cancer--is the jury in yet?
    Kaye SB
    J Natl Cancer Inst; 1997 Jul; 89(13):902-3. PubMed ID: 9214663
    [No Abstract]   [Full Text] [Related]  

  • 5. Expression of the breast cancer resistance protein in breast cancer.
    Faneyte IF; Kristel PM; Maliepaard M; Scheffer GL; Scheper RJ; Schellens JH; van de Vijver MJ
    Clin Cancer Res; 2002 Apr; 8(4):1068-74. PubMed ID: 11948115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biology of the multidrug resistance-associated protein, MRP.
    Loe DW; Deeley RG; Cole SP
    Eur J Cancer; 1996 Jun; 32A(6):945-57. PubMed ID: 8763335
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
    Kim R; Osaki A; Tanabe K; Kojima J; Toge T
    Oncol Rep; 2001; 8(3):597-603. PubMed ID: 11295087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy.
    Linn SC; Pinedo HM; van Ark-Otte J; van der Valk P; Hoekman K; Honkoop AH; Vermorken JB; Giaccone G
    Int J Cancer; 1997 May; 71(5):787-95. PubMed ID: 9180147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological considerations in the modulation of multidrug resistance.
    Fisher GA; Lum BL; Hausdorff J; Sikic BI
    Eur J Cancer; 1996 Jun; 32A(6):1082-8. PubMed ID: 8763350
    [No Abstract]   [Full Text] [Related]  

  • 10. Anthracycline resistance: the problem and its current definition.
    Gianni L
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-11-S10-17. PubMed ID: 9275001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Predictive factors for response to chemotherapy in breast cancers].
    Miyoshi Y; Noguchi S
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():154-9. PubMed ID: 17682152
    [No Abstract]   [Full Text] [Related]  

  • 12. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
    Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
    Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
    Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How circulating tumor cells escape from multidrug resistance: translating molecular mechanisms in metastatic breast cancer treatment.
    Gradilone A; Raimondi C; Naso G; Silvestri I; Repetto L; Palazzo A; Gianni W; Frati L; Cortesi E; Gazzaniga P
    Am J Clin Oncol; 2011 Dec; 34(6):625-7. PubMed ID: 22101388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversing antibiotic resistance.
    Hodgkinson R; Sharples D
    Expert Opin Investig Drugs; 2002 Aug; 11(8):1023-32. PubMed ID: 12150699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein mediated multidrug resistance and its implications for pathology.
    Trambas CM; Muller HK; Woods GM
    Pathology; 1997 May; 29(2):122-30. PubMed ID: 9213329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining MDR1/P-glycoprotein expression in breast cancer.
    Faneyte IF; Kristel PM; van de Vijver MJ
    Int J Cancer; 2001 Jul; 93(1):114-22. PubMed ID: 11391630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of anthracycline-resistant metastatic breast carcinoma].
    Kreienberg R
    Praxis (Bern 1994); 1998 Apr; 87(17):573-7. PubMed ID: 9623323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying Anthracycline Therapy Resistance in Breast Cancer.
    Liu Z; Gao J; Gu R; Shi Y; Hu H; Liu J; Huang J; Zhong C; Zhou W; Yang Y; Gong C
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.